We wish to inform you that on 31st March 2012, the biotechnology company Prosidion Ltd. ceased all activities at its facility in Oxford.

Prosidion is a subsidiary of Astellas Pharma Inc.

Astellas Pharma Inc. will assume responsibility for handling any administration relating to the closure of the site.

All enquiries relating to Prosidion that arise after the 31st March 2012 should be directed to Astellas:

Tel: +44 (0)1784 419 400

Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Website: www.astellas.com